Dehong Li to Humans
This is a "connection" page, showing publications Dehong Li has written about Humans.
Connection Strength
0.028
-
Li X, Mamouni K, Zhao R, Bai L, Chen Y, Wu Y, Xie ZR, Sautto GA, Liu D, Bowen NJ, Danaher A, Li D, Cook N, Grayson S, Zhu J, Coleman IM, Nelson PS, Bao Q, Zhou J, Osunkoya AO, Kucuk O, Gera L, Wu D. Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer. Br J Cancer. 2025 Jun; 132(12):1188-1199.
Score: 0.010
-
Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models. Br J Cancer. 2023 09; 129(5):884-894.
Score: 0.009
-
Ogunbona OB, Lin X, Hornick JL, Lubin DJ, Wang Q, Reid MD, Schneider F, Li D, Shin DM, Shi Q. Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma. J Am Soc Cytopathol. 2022 Jul-Aug; 11(4):183-193.
Score: 0.008